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Abstract
Patterns of expressed genes examined in cryopreserved peripheral blood mononuclear cells (PBMCs) of seropos-
itive persons electing to stop antiretroviral therapy in the AIDS Clinical Trials Group Study A5170 were scru-
tinized to identify markers capable of predicting the likelihood of CD4 T-cell depletion after cessation of an-
tiretroviral therapy (ART). A5170 was a multicenter, 96-week, prospective study of HIV-infected patients with
immunological preservation on ART who elected to interrupt therapy. Study entry required that the CD4 count
was greater than 350 cells/mm3 within 6 months of ART initiation. Median nadir CD4 count of enrollees was
436 cells/mm3. Two cohorts, matched for clinical characteristics, were selected from A5170. Twenty-four pa-
tients with an absolute CD4 cell decline of less that 20% at week 24 (good outcome group) and 24 with a CD4
cell decline of 20% (poor outcome group) were studied. The good outcome group had a decline in CD4 T-
cell count that was 50% less than the poor outcome group. Significance analysis of microarrays identified dif-
ferential gene expression (DE) in the two groups in data obtained from Affymetrix Human FOCUS GeneChips.
DE was significantly higher in the poor outcome group than in the good outcome group. Prediction analysis
of microarrays (PAM-R) identified genes that classified persons as to progression with greater than 80% accu-
racy at therapy interruption (TI) as well as at 24 weeks after TI. Gene set enrichment analysis (GSEA) identi-
fied a set of genes in the Ras signaling pathway, associated with the downregulation of apoptosis, as signifi-
cantly upregulated in the good outcome group at cessation of ART. These observations identify specific host
cell processes associated with differential outcome in this cohort after TI.
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Introduction
THE LIFESAVING ADVANTAGES OF ANTIRETROVIRAL THERAPY(ART) are evident. So too are the challenges faced by per-
sons who fail therapy, experience significant adverse side ef-
fects from treatment, or suffer treatment fatigue. As more is
learned about ART and treatment modalities evolve, persons
who initiated ART under previous guidelines to “hit early
and hit hard” would not currently be placed on ART.1,2 At
the other end of the spectrum are persons whose treatment
options are crucially narrowed due to multidrug resistance
or drug-related toxicities. Several studies have evaluated
therapy interruption (TI) in closely monitored clinical trials
involving primarily chronically infected persons on sus-
tained ART with stable suppression of viremia and pre-
served CD4 T-cell counts (generally above 350 cells/l).3–7
In addition to possibly alleviating the significant clinical side
effects and other burdens of prolonged ART, TI was initially
postulated to induce the emergence of a more drug-sensitive
virus (wild type) in persons with multidrug resistance8,9 or
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in an increase in HIV-specific immunity following cycles of
TI.10–13 Enhanced HIV-specific immune response, mediated
by the expansion of CD8 T cells, was postulated to enhance
T-cell turnover rates14 and speed of viral clearance,11 lower
viral set point, and/or to delay viral rebound, even if tem-
porarily.7,12,15
Encouraging observations reporting modest association
between increased HIV-specific CD8 memory cells and
suppression of viral replication in the earliest trials of TI16,17
involving small numbers of persons were discounted as the
preponderance of evidence from larger studies in chronically
infected persons with several rounds of TI of varying dura-
tion failed to define clear benefits of TI.5–7,12,13,15,18–20 TI in
acute or early HIV infection was associated with similar vi-
ral rebound.10,21 Explanations for these observations include
the failure of the transient and modest HIV-specific immu-
nity and the associated expansion of CD8 T cells generated
by TI to generate an effective long-term control of viral repli-
cation.11,12,15 Additionally, reservoirs of persistent replica-
tion competent virus may be preserved even during sus-
tained ART and emerge during TI.10,13,15 Concomitant with
viral rebound following TI, drug-resistant variants may
emerge.22
Transient increases in CD4 T cells, modest expansion of
viral-specific immunity, the fleeting emergence of wild-type
virus, and some association with a temporarily lowered rate
of clinical progression are seen after TI in some studies. How-
ever, the repercussions of viral rebound and the inability of
the TI-associated immune response to result in a substantial
and durable reduction in viral set point make the use of TI
untenable in the clinical management of seropositive per-
sons.23 The SMART study, the largest interventional study
conducted in HIV-seropositive persons, recently revealed
that TIs are associated with a significant increase in risk of
morbidity and mortality from events, many cardiovascular
in nature, not previously considered to be HIV-associated
and suggested that there was no benefit associated with TI
in any subpopulation of patients in the study.24
Nevertheless, in the context of research to identify corre-
lates of disease progression, samples derived from TI clini-
cal studies have the potential to provide critical information
on the performance and utility of the gold standard corre-
lates of HIV disease progression, such as CD4 T-cell levels,
viral load, and definitive clinical endpoints, as they can be
assessed dynamically, in the short term, and in the context
of extensive clinical evaluation. Importantly, these well-doc-
umented clinical studies also offer the opportunity to eval-
uate new and novel approaches to the assessment of risk of
disease progression. The identification of biomarkers, in
turn, builds the collection of tools for the assessment of both
drug interventions for the control of HIV disease and the
performance of vaccines for the prevention of HIV disease.
We studied samples from persons enrolled in a TI trial,
ACTG 5170, which determined that the incidence of clinical
endpoints was reduced and that the time to these endpoints
was prolonged in persons with higher CD4-cell nadir on
ART, lower viral loads prior to ART, and a viral load below
detection at TI.6 We sought to determine if patterns of gene
expression in the peripheral blood mononuclear cell (PBMC)
compartment, a type of sample consistently and easily avail-
able from clinical studies, might be correlated with the course
of disease upon TI. Our findings identified specific host-cell
processes in the PBMC compartment that are associated with
differential outcome after TI.
Materials and Methods
Clinical specimens
PBMCs were obtained with informed consent from study
volunteers enrolled in ACTG 5170, a multicenter clinical trial
approved by local human use institutional review boards.
Eligibility criteria for ACTG 5170 included confirmed HIV-
1 infection, age  12, CD4 count  350 cells/mm3 immedi-
ately prior to first ART, CD4 count  350 cells/mm3, plasma
HIV-1 RNA viral load  55,000 copies/ml at screening, cur-
rently receiving ART with 2 drugs for 6 months, and
Karnofsky score 70.6
A5170 was a multicenter, 96-week, prospective study of
HIV-infected patients with immunological preservation on
ART who elected to interrupt therapy. Study entry required
that the CD4 count was greater than 350 cells/mm3 within
6 months of ART initiation. Median nadir CD4 count of en-
rollees was 436 cells/mm3. Two cohorts, matched for clini-
cal characteristics, were selected from A5170. Twenty-four
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TABLE 1. DESCRIPTIVE STATISTICS FOR THE STUDY GROUPS
Good outcome group Poor outcome group
Statistic (n  24) (n  24)a p values
CD4 cells at week 0 798.35  224.30 900.71  236.46 0.146
CD4 cells at week 24 675.13  212.31 499.54  165.45 4.00  10	3
Delta CD4 cells 	123.23  127.31 	401.17  204.05 1.22  10	7
Viral load at week 0 1.716  0.064 1.726  0.067 0.157
Viral load at week 24 3.467  0.832 4.432  0.828 5.96  10	4
Delta viral load 1.716  0.856 2.705  0.817 6.43  10	4
Gender 23 M/1F 22 M/2 F
Age 41.50  8.85 41.00  6.71 0.650
Values are the mean  the standard deviation. p values were determined using the Wilcoxon rank-sum test. Viral load is expressed as log10
copies of viral RNA per milliliter of plasma. Values of viral load below the assay cut off of 50 copies were scored as 50 copies. CD4 T-cell lev-
els are expressed as number of cells per milliliter.
aClinical data for two of the samples in the poor outcome group were taken at week 12 and 16 and for one of the samples in this group at
week 4. GeneChip data was within 6–8 weeks of the clinical data. One sample in the poor outcome group had both clinical and GeneChip data
from week 32.
patients with an absolute CD4 cell decline of less that 20%
at week 24 (good outcome group) and 24 with a CD4 cell de-
cline of 20% (poor outcome group) were studied. The good
outcome group had a decline in CD4 T-cell count that was
50% less than the poor outcome group. The good outcome
group never reinitiated ART over the course of the study
while nine persons in the poor outcome group reinitiated
ART at a CD4 T-cell decline of 40%. PBMCs were col-
lected by Histopaque-Ficoll (Sigma, St. Louis, MO) gradient
centrifugation and were cryopreserved. Samples were as-
sessed for gene expression patterns at the time of cessation
of ART (week 0 in our study) and at 24 weeks after TI.
Standard measures of disease progression
The Roche Amplicor HIV Monitor test (version 1.5: Roche
Diagnostics, Basel, Switzerland) was used to determine
plasma viral load.
Peripheral blood lymphocyte subset analysis was per-
formed on a FACS Calibur flow cytometer (Becton-Dickin-
son, Mountain View, CA) using a panel of mouse anti-hu-
man monoclonal antibodies according to the manufacturer.
Gene expression profile analysis using 
Affymetrix GeneChips
Preparation of cellular RNA and subsequent processing
for GeneChip analysis were performed as described previ-
ously25 using the Agilent 2100 Bioanalyzer system (Agilent
Technologies, Santa Clara, CA) to assess the integrity and
quantity of RNA and the Affymetrix Human Focus
GeneChip (Affymetrix, Santa Clara, CA). This platform con-
sists of 8700 probe sets and assesses 8500 transcripts for 8400
full-length and fully annotated genes.
GeneChips with a scaling factor greater than 50 and an ar-
ray outlier percentage greater than 5% on dCHIP200526 were
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Poor group at wk 0
Good group at wk 0
Poor group at wk 24
Good group at wk 24
Functional categories of No. of genes p values
133 up regulated genes
Response to virus 12 4.58E-11
M phase of mitotic cell cycle 9 3.44E-05
Mitotic sister chromatid segregation 4 6.28E-04
Regulation of progression through cell cycle   12 1.57E-03
Inflammatory response 8 1.81E-03
Innate immune response 5 2.39E-03
Chemotaxis 6 3.65E-03
Regulation of apoptosis 9 8.80E-03
Regulation of programmed cell death 9 9.09E-03
DNA metabolism 13 9.15E-03
Cellular defense response 5 1.06E-02
Humoral immune response 6 1.15E-02
Positive regulation of programmed cell death  6 1.15E-02
Humoral defense mechanism 5 1.62E-02
Apoptosis 11 1.67E-02
Cation homeostasis 5 1.90E-02
Complement activation 3 3.64E-02
Functional Categories of No. of genes p values
208 down regulated genes
Protein biosynthesis 58 2.13E-26
Macromolecule biosynthesis 59 5.33E-25
Cellular protein metabolism 75 6.07E-07
Regulation of protein biosynthesis 7 9.28E-03
Regulation of cellular biosynthesis 7 1.14E-02
Functional categories of No. of genes p value
51 up regulated genes
response to virus 5 8.18E-05
cellular defense response 4 3.35E-03
biopolymer catabolism 5 5.16E-03
protein catabolism 4 2.80E-02
-2.0 1:1 2.0Green: down regulated Red: Up regulated
A
B
FIG. 1. Differential gene expression at 24 weeks after cessation of ART. (A) Differential expression in poor outcome group.
There were 133 genes upregulated and 208 genes downregulated at significant level of false discovery rate (FDR)  1%. On
the left is a heat map showing the magnitudes of gene expression changes (see Supplementary Table 1 for expression val-
ues of each gene in each sample). Gene ontology (GO) categories of these 133 up- and 208 downregulated genes are shown
on the right. Only categories whose p values are less than 0.05 are listed. The p values of each GO category were deter-
mined by the online tool, DAVID. (B) Differential expression in the good outcome group. Unlike the poor outcome group,
the number of differentially expressed genes in the good outcome group was much less. There were only 51 genes upreg-
ulated from week 0 to week 24 at FDR  1% significant level, and no genes downregulated at FDR  1% significant level.
eliminated from further analysis. CEL files were normalized
at the probe level using the robust multichip average
method27 built into the BioConductor package Affy-1.12.2.
Genes scored as absent in all 96 samples were eliminated
from analysis.
The Affymetrix datasets used to derive the observations
discussed in this article can be accessed at: http://www.ncbi.
nlm.nih.gov/geo/ under the accession numbers: GSE 10924.
Gene expression data analysis methods
Differentially expressed genes were identified by using the
statistical program Significance Analysis of Microarrays
(SAM) version 3.028 and cluster analysis of microarray
datasets was performed using MultiExperiment Viewer
available at http://www.tigr.org/software/microarray.
shtml. SAM identifies genes whose expression has signifi-
cantly changed by leveraging a set of gene-specific t tests.
Genes are assigned a score derived from the change in ex-
pression relative to the standard deviation for all measure-
ments made for that gene. Genes that exceed a threshold are
scored as statistically significant. The percentage of genes be-
ing called significant by chance is measured by false dis-
covery rate (FDR). We used a cutoff of FDR  1% for SAM,
which is very stringent.
The functions and biological classifications of differen-
tially expressed genes were analyzed by the web-based tool,
DAVID, which sorts gene lists into functional profiles using
broad gene ontology categories by associated biological pro-
cesses.29 Ontology groupings for genes overlap by nature of
the fact that the products of genes may have multiple func-
tions.
Class prediction was performed using an academic soft-
ware package, Prediction Analysis of Microarray with R
(PAM-R), which implemented the nearest shrunken centroid
algorithm.30 The software provides a k-fold cross-validation
method to estimate the predicting capability of the resultant
classifier set of genes. PAM-R is available at http://www.
bioconductor.org. PAM-R is an iterative analytical method
that uses sets of individual genes, called classifier sets, that
together are capable of assigning samples to a given group.
Gene set enrichment analysis (GSEA) or R-GSEA and
MSigDB (Molecular Signatures DataBase of gene sets) were
used to identify differentially expressed sets of genes. Both
the software and geneset database were downloaded from
the website of The Broad Institute of MIT and Harvard
(http://www.broad.mit.edu). GSEA identifies sets of related
genes, as opposed to individual genes, associated with bio-
logical pathways that are coregulated and are associated
with progression after TI in our study. We used GSEA’s de-
fault statistical cutoff FDR  0.25.
Independent confirmation of GeneChip expression data
To confirm observations from the gene chip data, Taq-
Man® Gene Expression Assays (Applied Biosystems, Foster
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FIG. 2. Survey of the distribution of genes significantly upregulated in the
poor and good outcome groups. The numbers of genes in the ontological
groups as determined by DAVID are given as well as the associated p val-
ues for each. Common to both groups were genes associated with viral in-
fection. Distinct in the poor and good outcome groups were genes associ-
ated with catabolism and in the poor group were those associated with
apoptosis, programmed cell death, and progression through the cell cycle.
City, CA) optimized for microarray validation (3’ most) were
used to detect NFKB1, RELA, RAF1, and PIK3CA in three
randomly chosen, matched sets of good and poor outcome
samples. The fluorescence signals were measured in real time
using ABI HT7900 and critical threshold (CT) values were
output from the software SDS2.1. Glyceraldehyde 3-phos-
phate dehydrogenase was used as internal control to calcu-
late fold changes of target genes in good versus poor out-




Demographic and clinical characteristics 
of the study group
There were 96 samples in the study set. Table 1 summarizes
the characteristics of the good and poor outcome groups at
week 0 (at cessation of ART) and 24 weeks later. The drop in
CD4 T cells in the samples in the good outcome group was
50% less than the corresponding matched sample in the poor
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FIG. 3. Classification analysis for outcome at week 0 and at week 24 after the cessation of antiretroviral therapy. (A) Pre-
diction analysis of microarrays (PAM-R) analysis of classification and prediction at week 0 showing an 81% accuracy in
classification by the 53 genes in the classifier set. (B) PAM-R analysis of classification and prediction at week 24 showing
an 83% accuracy in classification by the 176 genes in the classifier set. The x-axis (numbers 1 through 48) shows the patients
in the analysis with numbers 1–24 belonging to the good outcome group and numbers 25–48 to the poor outcome group.
For each patient, there are two symbols. A triangle indicates the probability, shown on the y-axis, of a patient being pre-
dicted to belonging in the good outcome group, and a cross indicates the probability of the same patient being predicted
as belonging to the poor outcome group. If a triangle is above a cross, the patient is classified as belonging to the good out-
come group and conversely, if a cross is above a triangle, the patient is classified as belonging to the poor outcome group.
For a given patient, the sum of all probabilities is always equal to 1.
outcome group. The good outcome group was characterized
by a mean loss of 123.23 cells over the study period, and the
poor outcome group by a mean loss of 401.17 cells (Wilcoxon
rank-sum test, p  1.22  10	7). At study entry, the two groups
had no significant difference in plasma viral load, CD4 T-cell
levels, or age. At week 24, there was a significant difference be-
tween the two groups in CD4 T cells, viral load, and the mean
change in both these parameters since study entry. The groups
do not differ in gender or race as 94% were male, 6% female
and 67% were Caucasian, 19% were African-American, 10%
Hispanic, and 4% Asian/Pacific Islander. There was no signif-
icant difference in the ART history in the two groups (data not
shown). Principal component analysis indicated that expression
profiles of samples in the poor outcome group taken at weeks
4, 12, 16, and 32 were not outliers.
Differential gene expression is associated with
progression after the cessation of ART
SAM using study entry (week 0) as baseline, with an FDR
of 1%, was used to identify genes that exhibited a significant
change in expression level over the 24-week study period.
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FIG. 4. Functional categories of genes comprising the classification sets at week 0 and at week 24. (A) Pie chart of those
functional categories in the classifier set at week 0 that were annotated by DAVID at biological process level 5. Genes as-
sociated with progression through the cell cycle are included. (B) Pie chart of those functional categories in the classifier
set at week 24 that were annotated by DAVID. Genes associated with the regulation of apoptosis and cell cycle predomi-
nated. Only genes with p value of  0.05 are shown.
Differentially expressed (DE) genes were annotated using
the DAVID database to determine significantly enriched
gene ontology (GO) functional categories with a cutoff p
value of 0.05. The complete list of differentially expressed
genes is given in the Appendix.
More differential expression was observed in the poor
outcome group over the study period than in the good out-
come group at an FDR of 1%. Figure 1 is a heat map show-
ing the upregulation of 133 genes and the downregulation
of 208 genes in the poor outcome group over the 24-week
period. Also shown are the remarkably few genes, 51 up-
regulated and no significantly downregulated genes,
whose expression was significantly changed over the study
period in the good outcome group. Corresponding GO
functional categories are also shown. Genes associated
with response to viral infection were among those upreg-
ulated. The DE genes that were downregulated at week 24
were dominated by those associated with biosynthesis and
metabolism.
In the good outcome group, 51 genes were differentially
expressed over the study period and none were downregu-
lated. Genes associated with response to viral infection and
cellular defense predominated the set of upregulated genes
in the good outcome group.
Figure 2 displays a Venn diagram of the differences and
similarities between DE in the good and poor outcome
groups in genes that are upregulated over the 24-week pe-
riod. There were 15 genes that were upregulated and were
unique to the good outcome group. Thirty-six upregulated
genes were observed in both outcome groups, and 97 up-
regulated genes were unique to the poor outcome group. The
major functional categories that comprise the upregulated
genes shared by both groups were those associated with re-
sponse to virus (five genes) and with cellular defense re-
sponse (four genes). Functional categories unique to the poor
outcome group included apoptosis, inflammatory response,
and the positive regulation of programmed cell death, and
those associated with catabolism were uniquely upregulated
in the good outcome group.
DE of sets of genes is capable of classifying patients as
to progression after the cessation of ART with greater
than 80% accuracy
PAM-R was used to leverage a 10-fold cross-validation
method to identify sets of classifier genes capable of sorting
samples into good and poor outcome groups. Figure 3(A)
and (B) show the results of PAM-R at study entry and week
24, respectively. The graph in Fig. 3(A) shows that, leverag-
ing the expression of a distinct set of genes, samples can be
assigned to the good or poor group with an overall accuracy
of 81% at study entry. The resolution of the assignment of
samples to the two groups increased significantly by 24
weeks, shown in Fig. 3(B), as indicated by the increase in the
separation of the probability of assignment to the correct
group shown on the ordinate. Figure 4(A) and (B) show pie
charts of the known functional categories of the 53 genes
comprising the 81% accurate classifier set at study entry and
the 176 genes comprising the 83% accurate classifier set at
week 24.
Of the genes in the 53 gene classifier set at study entry
that can be annotated by DAVID and have a p value of less
than 0.05, genes associated with the regulation of pro-
gression through the cell cycle were observed. In the 176
gene classifier set at week 24, genes associated with the
regulation of apoptosis and progression through the cell
cycle dominate and those associated with the immune re-
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FIG. 5. Gene set enhancement analysis and identification
of genes in the Ras signaling pathway associated with the
regulation of apoptosis at week 0. (A). Heat map showing
the differential expression of genes in the Ras signaling path-
way in the two outcome groups. (B) Network of Ras signal-
ing pathway genes identified by gene set enrichment analy-
sis. The expression of genes whose annotations are given in
red ink was independently confirmed by reverse-transcrip-
tase polymerase chain reaction. ERK 1/2, extracellular sig-
nal regulated kinase; Ras, Regulator GTPase, rat sarcoma 
viral oncogene; PIK3 CA, phosphatidylinositol e kinase cat-
alytic subunit A isoform; RAC1, Ras-related botulinum toxin
substrate 1; PIP3 phosphoinositide binding protein 3; RAF1,
vraf 1 murine leukemia viral oncogene homolog 1; NFKB1,
nuclear factor of kappa light polpeptide gene enhancer in B
cells 1; RELA, vref reticuloendotheliosis viral oncogene ho-
molog A.
sponse, viral infection, and proliferation are also repre-
sented.
High-resolution gene set enrichment analysis identified
genes in the Ras pathway that are specifically associated
with the downregulation of apoptosis and that are
differentially enriched in samples from patients 
with good outcome
High-resolution gene set enrichment analysis was used
to identify sets of genes known as “core enrichment genes,”
which are differentially expressed at week 0, the point of
cessation of ART. The results of this analysis are shown in
Fig. 5(A) and (B). Figure 5(A) displays a heat map show-
ing the expression of the set of core enrichment genes in
the Ras family that were identified by GSEA as being up-
regulated in the good outcome group. The Ras genes iden-
tified by GSEA were associated with the modulation of
apoptosis. The functional pathway of these genes is shown
in Fig. 5(B). The expression of genes whose annotations are
shown in red ink in Fig. 5(B) were independently con-
firmed by reverse-transcriptase (RT) polymerase chain re-
action (PCR).
Real-time PCR confirmed the expression of the 
genes in the Ras pathway that were upregulated 
in the good outcome group
Table 2 summarizes the confirmation by RT PCR of the
DE in randomly chosen, matched samples from the good
and poor outcome groups at the time of cessation of ART
and identified by the expression data as genes associated
with the regulation of apoptosis in the Ras signaling path-
way. The correlation coefficient for the concordance of
these two independent means of deriving the data was r 
0.93.
Discussion
The goal of this study was to ascertain if, prior to ART in-
terruption, distinct patterns of gene expression might be as-
sociated with disease progression or outcome in persons who
stop ART. A second goal of the study was to use these pat-
terns to identify biological and cellular processes that might
account for such an association. Clearly, the good and poor
outcome groups were indistinguishable by demographic and
traditional clinical features at the time of cessation of ART
(week 0) and were by week 24 significantly divergent in clin-
ical status. Accordingly, there are definitive patterns of gene
expression associated with the two groups at week 24. Al-
though this might be expected after clinical progression has
occurred, the observation that gene expression patterns that
are associated with outcome at week 24 can be identified at
week 0 is highly significant.
Genes associated with apoptosis are shown by the three
levels of analysis used in our study to be indicative of dif-
ferential outcome. SAM analysis indicates that these genes
are uniquely upregulated by week 24 in the poor outcome
group. The more stringent classification analysis indicates
that by week 24, genes associated with the regulation of
apoptosis are represented in the 176 genes capable of classi-
fication of samples into two divergent groups with an accu-
racy of 83%. Classification analysis also indicates that there
are patterns of gene expression that are capable of distin-
guishing the two groups at week 0. The analysis presented
in Fig. 3(A and B) is critical for several reasons in that: (1) it
demonstrates the degree to which expression profiles can
distinguish differential outcome after TI and 24 weeks later
and (2) it shows that such profiles can distinguish differen-
tial outcome as early as study entry when the traditional
markers of CD4 T-cell levels and viral load are indistin-
guishable. In addition, this analysis provides the collection
of genes that drive the prediction of outcome and that in-
clude those associated with the regulation of cell cycle and
apoptosis as shown in Fig. 4(A and B). These data prompted
the GSEA, which confirmed and extended the identification
of the modulation of apoptosis as the underlining functional
pathway that distinguished good and poor outcome persons.
The extensive scrutiny of gene expression at week 0 by
GSEA identified a set of genes, as opposed to individual genes,
that are associated with the regulation of apoptosis in the Ras
signaling pathway. Independent confirmation of the differen-
tial expression data generated by gene chip analysis, using
RT-PCR in both good and poor outcome samples, further sub-
stantiated the pivotal role of this gene family in disease course
immediately after the cessation of ART. Taken together, these
data indicated that the regulation of apoptosis may play a sig-
nificant role in the pathogenesis of disease after the cessation
of ART. Furthermore, as there appeared to be little difference
in HIV pathogenesis after the initial establishment of viral set
point following infection and after the reestablishment of vi-
ral set point following TI, the regulation of apoptosis may play
an important role in HIV pathogenesis throughout the course
of HIV infection. Observations in the nonhuman primate
model report a species-specific, divergent immune response
in a natural host (sooty mangabey) and a nonnatural host (rhe-
sus macaque) that is evident from the time of infection with
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TABLE 2. RT-PCR CONFIRMATION OF THE UPREGULATION OF RAS SIGNALING PATHWAY IN GOOD OUTCOME GROUP AT WEEK 0
PIK3CA RAF1 NFKB1 RELA
RT-PCR GeneChip RT-PCR GeneChip RT-PCR GeneChip RT-PCR GeneChip
1.89 1.54 1.43 1.18 0.69 0.79 1.29 1.12
3.33 4.91 1.00 1.86 1.89 2.24 1.63 2.11
4.06 4.25 2.03 2.46 5.00 5.28 1.86 1.37
Values in the table are the fold changes of good versus matched poor samples. For each gene, the left column is fold change detected by RT-
PCR and the right column is fold changes measured by GeneChip in three sets of samples. Correlation coefficient of GeneChip and RT-PCR
data is 0.93. The fold change was calculated by 2	

CT method using GAPDH as internal control. RT, reverse-transcriptase; PCR, polymerase
chain reaction.
uncloned simian immunodeficiency virus, sooty mangabey
(SIVsm). Both hosts developed high levels of viremia but in
the sooty mangabey, an attenuated immune response was cor-
related with an absence of CD4 T-cell decline and simian im-
munovirus (SIV)-associated pathogenesis. These observations
suggest that the host response to infection plays a critical role
in SIV, and by extension, HIV, pathogenesis.31 Similar obser-
vations have been reported in three HIV-seropositive persons
who are long-term nonprogressors.32
The Ras signaling pathway is the specific gene family as-
sociated by GSEA with differential outcome after TI. Ras,
named for its association with rat sarcoma viral oncogenes,
is an extensively studied small guanosine triphosphatase
protein33 that relays extracellular signals to intracellular sig-
naling cascades. The protein plays a pivotal role in the com-
plex positive and negative feedback loops that modulate cell
survival and cell death, as well as cell proliferation and dif-
ferentiation.34–36 Understandably, this protein has been scru-
tinized by the oncology field as a potential drug target to
halt the transformation and unchecked growth associated
with cancer.37 In our study, the cascade of the convoluted
Ras signaling pathway that is associated with differential
outcome after TI involved impingement on PI3K (also
known as PIK3CA, phosphatidylinositol 3 kinase catalytic
subunit, alpha isoform) and ERK (extracellular signal regu-
lated kinase)/RAF 1 (vraf1 murine leukemia viral oncogene
homolog 1). Among the myriad of regulatory pathways in-
volving Ras, the pathway associated with good outcome in
our study modulates antiapoptotic processes.35,38,39 Gene ex-
pression patterns of PI3K, RELA (v-rel riticuloendotheliosis
viral oncogene, homolog A), NFkB1 (nuclear factor of kappa
light chain polypeptide gene enhancer in B cells 1), and RAF
1 identified by GSEA support the conclusion that this cas-
cade, which directs the downregulation of apoptosis,35,38,39
is associated with differential outcome in our study.
Modulation of cell survival by the Ras signaling pathway
has been shown to depend on cell type and level of gene ex-
pression.38,40 However, the assessment of the transcriptional
patterns within the total PBMC compartment cannot pin-
point causal processes within a particular cellular subcom-
partment or to a specific functional protein. Nevertheless,
downregulation of apoptosis in the good outcome group, as
assessed in the PBMC compartment, was associated with a
statistically significant, fourfold less decline in CD4 T cells
than observed in the poor outcome group. This observation
is consistent with that of van Grevenynghe and colleagues,
who reported that the central memory CD4 T cells of elite
controllers were less susceptible to Fas-regulated apopto-
sis.41 It is also important to note that persons with higher
CD4 cell nadir while on ART exhibited a delayed time to
the development of primary clinical end points in the study
from which these samples were drawn.6 Observations from
the SMART study that addressed outcome during episodic
antiretroviral therapy guided by CD4 T cell counts showed
a significantly increased risk of opportunistic infections and
death compared with continuous therapy, which was pos-
tulated to be due to a decline in CD4 T cells and concomi-
tant increase in viral load.24 Furthermore, that gene expres-
sion patterns associated with the downregulation of
apoptosis in the good outcome group could be distinguished
so early (week 0) may indicate that such patterns had been
established prior to the cessation of ART.
The identification of a set of genes definitively associated
with the downregulation of cell death as an attribute of the
good outcome group is a reasonable point of departure for
future studies on specific subpopulations of cells or in ani-
mal models that might confirm and extend our observations
to specific cell types or tissues. Ultimately, candidate bio-
markers such as these, determined in well controlled clini-
cal studies in which the traditional makers of viral load and
CD4 T cells are well characterized, will need to be evalu-
ated in prospective clinical studies.
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APPENDIX: FULL ANNOTATION INFORMATION FOR DIFFERENTIALLY EXPRESSED GENES
Chromosome
ProbesetIDs Symbols PublicID UniGeneID location Gene title
Good outcome group: 51 up regulated genes
206486_at LAG3 NM_002286 Hs.409523 chr12p13.32 Lymphocyte-activation gene 3
203554_x_at PTTG1 NM_004219 Hs.350966 chr5q35.1 Pituitary tumor-transforming 1
202589_at TYMS NM_001071 Hs.592338 chr18p11.32 Thymidylate synthetase
200986_at SERPING1 NM_000062 Hs.384598 chr11q12-q13.1 Serpin peptidase inhibitor, clade G
(C1 inhibitor), member 1
209773_s_at RRM2 BC001886 Hs.226390 chr2p25-p24 Ribonucleotide reductase M2
polypeptide
206666_at GZMK NM_002104 Hs.277937 chr5q11-q12 Granzyme K (granzyme 3; tryptase II)
218039_at NUSAP1 NM_016359 Hs.615092 chr15q15.1 Nucleolar and spindle-associated
protein 1
214453_s_at IFI44 NM_006417 Hs.82316 chr1p31.1 Interferon-induced protein 44
207840_at CD160 NM_007053 Hs.488237 chr1q21.1 CD160 molecule
206513_at AIM2 NM_004833 Hs.281898 chr1q22 Absent in melanoma 2
204439_at IFI44L NM_006820 Hs.389724 chr1p31.1 Interferon-induced protein 44-like
205483_s_at ISG15 NM_005101 Hs.458485 chr1p36.33 ISG15 ubiquitin-like modifier
200629_at WARS NM_004184 Hs.497599 chr14q32.31 Tryptophanyl-tRNA synthetase
204747_at IFIT3 NM_001549 Hs.47338 chr10q24 Interferon-induced protein with
tetratricopeptide repeats 3
204639_at ADA NM_000022 Hs.255479 chr20q12-q13.11 Adenosine deaminase
216615_s_at HTR3A AJ005205 Hs.413899 chr11q23.1 5-hydroxytryptamine (serotonin)
receptor 3A
201649_at UBE2L6 NM_004223 Hs.425777 chr11q12 Ubiquitin-conjugating enzyme E2L 6
204224_s_at GCH1 NM_000161 Hs.86724 chr14q22.1-q22.2 GTP cyclohydrolase 1 (dopa-responsive
dystonia)
217933_s_at LAP3 NM_015907 Hs.570791 chr4p15.32 Leucine aminopeptidase 3
213060_s_at CHI3L2 U58515 Hs.514840 chr1p13.3 Chitinase 3-like 2 /// chitinase 3-like 2
209040_s_at PSMB8 U17496 Hs.180062 chr6p21.3 Proteasome (prosome, macropain)
subunit, beta type, 8
200887_s_at STAT1 NM_007315 Hs.651258 chr2q32.2 Signal transducer and activator
of transcription 1, 91kDa
204246_s_at DCTN3 NM_007234 Hs.511768 chr9p13 Dynactin 3 (p22)
202086_at MX1 NM_002462 Hs.517307 chr21q22.3 Myxovirus (influenza virus) resistance 1
218400_at OAS3 NM_006187 Hs.528634 chr12q24.2 2’-5’-oligoadenylate synthetase 3, 100kDa
203153_at IFIT1 NM_001548 Hs.20315 chr10q25-q26 Interferon-induced protein with
tetratricopeptide repeats 1
218943_s_at DDX58 NM_014314 Hs.190622 chr9p12 DEAD (Asp-Glu-Ala-Asp) box
polypeptide 58
205241_at SCO2 NM_005138 Hs.567405 chr22q13.33 SCO cytochrome oxidase-deficient
homolog 2 (yeast)
203232_s_at ATXN1 NM_000332 Hs.434961 chr6p23 Ataxin 1
200814_at PSME1 NM_006263 Hs.75348 chr14q11.2 Proteasome (prosome, macropain)
activator subunit 1
201274_at PSMA5 NM_002790 Hs.485246 chr1p13 Proteasome (prosome, macropain)
subunit, alpha type, 5
206991_s_at CCR5 NM_000579 Hs.450802 chr3p21.31 Chemokine (C-C motif) receptor 5
210046_s_at IDH2 U52144 Hs.596461 chr15q26.1 Isocitrate dehydrogenase 2 (NADP+),
mitochondrial
201762_s_at PSME2 NM_002818 Hs.434081 chr14q11.2 Proteasome (prosome, macropain)
activator subunit 2
215332_s_at CD8B AW296309 Hs.405667 chr2p12 CD8b molecule
204415_at IFI6 NM_022873 Hs.523847 chr1p35 Interferon, alpha-inducible protein 6
202095_s_at BIRC5 NM_001168 Hs.514527 chr17q25 Baculoviral IAP repeat-containing 5
(survivin)
200923_at LGALS3BP NM_005567 Hs.514535 chr17q25 Lectin, galactoside-binding, soluble,
3 binding protein
204655_at CCL5 NM_002985 Hs.514821 chr17q11.2-q12 Chemokine (C-C motif) ligand 5
218350_s_at GMNN NM_015895 Hs.234896 chr6p22.2 Geminin, DNA replication inhibitor
209714_s_at CDKN3 AF213033 Hs.84113 chr14q22 Cyclin-dependent kinase inhibitor 3
204173_at MYL6B NM_002475 Hs.632731 chr12q13.13 Myosin, light chain 6B, alkali, smooth
muscle and non-muscle
200633_at UBB NM_018955 Hs.356190 chr17p12-p11.2 Ubiquitin B /// ubiquitin B
(continued)
VAHEY ET AL.1058
APPENDIX: FULL ANNOTATION INFORMATION FOR DIFFERENTIALLY EXPRESSED GENES (CONTINUED)
Chromosome
ProbesetIDs Symbols PublicID UniGeneID location Gene title
44673_at SIGLEC1 N53555 Hs.31869 chr20p13 Sialic acid binding Ig-like lectin 1,
sialoadhesin
210243_s_at B4GALT3 AF038661 Hs.321231 chr1q21-q23 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 3
200961_at SEPHS2 NM_012248 Hs.118725 chr16p11.2 Selenophosphate synthetase 2
204798_at MYB NM_005375 Hs.531941 chr6q22-q23 V-myb myeloblastosis viral oncogene
homolog (avian)
204279_at PSMB9 NM_002800 Hs.132682 chr6p21.3 Proteasome (prosome, macropain)
subunit, beta type, 9
215313_x_at HLA-A AA573862 Hs.181244 chr6p21.3 Major histocompatibility complex,
class I, A
212203_x_at IFITM3 BF338947 Hs.374650 chr11p15.5 Interferon induced transmembrane
protein 3 (1-8U)
202411_at IFI27 NM_005532 Hs.532634 chr14q32 Interferon, alpha-inducible protein 27
Poor outcome group: 133 upregulated genes
214453_s_at IFI44 NM_006417 Hs.82316 chr1p31.1 Interferon-induced protein 44
204439_at IFI44L NM_006820 Hs.389724 chr1p31.1 Interferon-induced protein 44-like
204747_at IFIT3 NM_001549 Hs.47338 chr10q24 Interferon-induced protein with
tetratricopeptide repeats 3
219863_at HERC5 NM_016323 Hs.26663 chr4q22.1 Hect domain and RLD 5
203153_at IFIT1 NM_001548 Hs.20315 chr10q25-q26 Interferon-induced protein with
tetratricopeptide repeats 1
200986_at SERPING1 NM_000062 Hs.384598 chr11q12-q13.1 Serpin peptidase inhibitor, clade G
(C1 inhibitor), member 1
202748_at GBP2 NM_004120 Hs.386567 chr1p22.2 Guanylate binding protein 2,
interferon-inducible
205483_s_at ISG15 NM_005101 Hs.458485 chr1p36.33 ISG15 ubiquitin-like modifier
218400_at OAS3 NM_006187 Hs.528634 chr12q24.2 2’-5’-oligoadenylate synthetase 3,
100kDa
206486_at LAG3 NM_002286 Hs.409523 chr12p13.32 Lymphocyte-activation gene 3
202086_at MX1 NM_002462 Hs.517307 chr21q22.3 Myxovirus (influenza virus)
resistance 1
200923_at LGALS3BP NM_005567 Hs.514535 chr17q25 Lectin, galactoside-binding, soluble,
3 binding protein
44673_at SIGLEC1 N53555 Hs.31869 chr20p13 Sialic acid binding Ig-like lectin 1,
sialoadhesin
202270_at GBP1 NM_002053 Hs.62661 chr1p22.2 Guanylate binding protein 1,
interferon-inducible
202145_at LY6E NM_002346 Hs.521903 chr8q24.3 Lymphocyte antigen 6 complex, locus E
205241_at SCO2 NM_005138 Hs.567405 chr22q13.33 SCO cytochrome oxidase deficient
homolog 2 (yeast)
201786_s_at ADAR NM_001111 Hs.12341 chr1q21.1-q21.2 Adenosine deaminase, RNA-specific
208436_s_at IRF7 NM_004030 Hs.166120 chr11p15.5 Interferon regulatory factor 7
218039_at NUSAP1 NM_016359 Hs.615092 chr15q15.1 Nucleolar and spindle-associated
protein 1
204224_s_at GCH1 NM_000161 Hs.86724 chr14q22.1-q22.2 GTP cyclohydrolase 1 (dopa-responsive
dystonia)
218350_s_at GMNN NM_015895 Hs.234896 chr6p22.2 Geminin, DNA replication inhibitor
204415_at IFI6 NM_022873 Hs.523847 chr1p35 Interferon, alpha-inducible protein 6
203358_s_at EZH2 NM_004456 Hs.444082 chr7q35-q36 Enhancer of zeste homolog 2 (Drosophila)
204994_at MX2 NM_002463 Hs.926 chr21q22.3 Myxovirus (influenza virus) resistance 2
(mouse)
203554_x_at PTTG1 NM_004219 Hs.350966 chr5q35.1 Pituitary tumor-transforming 1
212203_x_at IFITM3 BF338947 Hs.374650 chr11p15.5 Interferon induced transmembrane
protein 3 (1-8U)
202411_at IFI27 NM_005532 Hs.532634 chr14q32 Interferon, alpha-inducible protein 27
212185_x_at MT2A NM_005953 Hs.647371 chr16q13 Metallothionein 2A
201762_s_at PSME2 NM_002818 Hs.434081 chr14q11.2 Proteasome (prosome, macropain)
activator subunit 2 (PA28 beta)
206914_at CRTAM NM_019604 Hs.159523 chr11q22-q23 Cytotoxic and regulatory T cell
molecule
206991_s_at CCR5 NM_000579 Hs.450802 chr3p21.31 Chemokine (C-C motif) receptor 5
207840_at CD160 NM_007053 Hs.488237 chr1q21.1 CD160 molecule
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202589_at TYMS NM_001071 Hs.592338 chr18p11.32 Thymidylate synthetase
210797_s_at OASL AF063612 Hs.118633 chr12q24.2 2’-5’-oligoadenylate synthetase-like
206133_at BIRC4BP NM_017523 Hs.441975 chr17p13.2 XIAP associated factor-1
204655_at CCL5 NM_002985 Hs.514821 chr17q11.2-q12 Chemokine (C-C motif) ligand 5
201649_at UBE2L6 NM_004223 Hs.425777 chr11q12 Ubiquitin-conjugating enzyme E2L 6
204858_s_at ECGF1 NM_001953 Hs.592212 chr22q13-22q13.33 Endothelial cell growth factor
1 (platelet-derived)
200629_at WARS NM_004184 Hs.497599 chr14q32.31 Tryptophanyl-tRNA synthetase
204204_at SLC31A2 NM_001860 Hs.24030 chr9q31-q32 Solute carrier family 31 (copper
transporters), member 2
216526_x_at HLA-C AK024836 Hs.77961 chr6p21.3 Major histocompatibility complex,
class I, C
205692_s_at CD38 NM_001775 Hs.479214 chr4p15 CD38 molecule
221485_at B4GALT5 AL035683 Hs.370487 chr20q13.1-q13.2 UDP-Gal:betaGlcNAc beta
1,4-galactosyltransferase,
polypeptide 5
218599_at REC8L1 NM_005132 Hs.419259 chr14q11.2-q12 REC8-like 1 (yeast)
210046_s_at IDH2 U52144 Hs.596461 chr15q26.1 Isocitrate dehydrogenase 2 (NADP+),
mitochondrial
206513_at AIM2 NM_004833 Hs.281898 chr1q22 Absent in melanoma 2
204211_x_at EIF2AK2 NM_002759 Hs.131431 chr2p22-p21 Eukaryotic translation initiation factor
2-alpha kinase 2
200887_s_at STAT1 NM_007315 Hs.651258 chr2q32.2 Signal transducer and activator of
transcription 1, 91kDa
203052_at C2 NM_000063 Hs.408903 chr6p21.3 Complement component 2
206461_x_at MT1H NM_005951 Hs.438462 chr16q13 Metallothionein 1H
217933_s_at LAP3 NM_015907 Hs.570791 chr4p15.32 Leucine aminopeptidase 3
204972_at OAS2 NM_016817 Hs.414332 chr12q24.2 2’-5’-oligoadenylate synthetase 2,
69/71kDa
202954_at PAK3 NM_007019 Hs.93002 chrXq22.3-q23 p21 (CDKN1A)-activated kinase 3
202345_s_at FABP5 NM_001444 Hs.632112 chr8q21.13 Fatty acid binding protein 5
(psoriasis-associated)
218943_s_at DDX58 NM_014314 Hs.190622 chr9p12 DEAD (Asp-Glu-Ala-Asp) box
polypeptide 58
202484_s_at MBD2 AF072242 Hs.25674 chr18q21 Methyl-CpG binding domain protein 2
202953_at C1QB NM_000491 Hs.8986 chr1p36.12 Complement component 1,
q subcomponent, B chain
201315_x_at IFITM2 NM_006435 Hs.174195 chr11p15.5 Interferon induced transmembrane
protein 2 (1-8D)
205552_s_at OAS1 NM_002534 Hs.524760 chr12q24.1 2’,5’-oligoadenylate synthetase 1,
40/46kDa
209773_s_at RRM2 BC001886 Hs.226390 chr2p25-p24 Ribonucleotide reductase M2 polypeptide
219684_at RTP4 NM_022147 Hs.43388 chr3q27.3 Receptor (chemosensory) transporter
protein 4
204533_at CXCL10 NM_001565 Hs.632586 chr4q21 Chemokine (C-X-C motif) ligand 10
203350_at AP1G1 NM_001128 Hs.461253 chr16q23 Adaptor-related protein complex 1,
gamma 1 subunit
202107_s_at MCM2 NM_004526 Hs.477481 chr3q21 MCM2 minichromosome maintenance
deficient 2, mitotin (S. cerevisiae)
215313_x_at HLA-A AA573862 Hs.181244 chr6p21.3 Major histocompatibility complex,
class I, A
201088_at KPNA2 NM_002266 Hs.632749 chr17q23.1-q23.3 Karyopherin alpha 2 (RAG cohort 1,
importin alpha 1)
210354_at IFNG M29383 Hs.856 chr12q14 Interferon, gamma
213475_s_at ITGAL AC002310 Hs.174103 chr16p11.2 Integrin, alpha L (antigen CD11A (p180)
35254_at TRAFD1 AB007447 Hs.5148 chr12q TRAF-type zinc finger domain
containing 1
218662_s_at NCAPG NM_022346 Hs.567567 chr4p15.33 Non-SMC condensin I complex,
subunit G
208683_at CAPN2 M23254 Hs.350899 chr1q41-q42 Calpain 2, (m/II) large subunit
203344_s_at RBBP8 NM_002894 Hs.546282 chr18q11.2 Retinoblastoma binding protein 8
203882_at ISGF3G NM_006084 Hs.1706 chr14q11.2 Interferon-stimulated transcription
factor 3, gamma 48kDa
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203050_at TP53BP1 NM_005657 Hs.440968 chr15q15-q21 Tumor protein p53 binding protein, 1
203258_at DRAP1 NM_006442 Hs.356742 chr11q13.3 DR1-associated protein 1 (negative
cofactor 2 alpha)
203455_s_at SAT1 NM_002970 Hs.28491 chrXp22.1 Spermidine/spermine N1-
acetyltransferase 1
203606_at NDUFS6 NM_004553 Hs.408257 chr5p15.33 NADH dehydrogenase (ubiquinone)
Fe-S protein 6, 13kDa
35974_at LRMP U10485 Hs.124922 chr12p12.1 Lymphoid-restricted membrane protein
205633_s_at ALAS1 NM_000688 Hs.476308 chr3p21.1 Aminolevulinate, delta-, synthase 1
219209_at IFIH1 NM_022168 Hs.163173 chr2p24.3-q24.3 Interferon induced with helicase C
domain 1
207614_s_at CUL1 NM_003592 Hs.146806 chr7q36.1 Cullin 1
216950_s_at FCGR1A X14355 Hs.77424 chr1q21.2-q21.3 Fc fragment of IgG, high-affinity Ia,
receptor (CD64)
202446_s_at PLSCR1 AI825926 Hs.130759 chr3q23 Phospholipid scramblase 1
214022_s_at IFITM1 AA749101 Hs.458414 chr11p15.5 Interferon induced transmembrane
protein 1 (9-27)
202863_at SP100 NM_003113 Hs.369056 chr2q37.1 SP100 nuclear antigen
204146_at RAD51AP1 BE966146 Hs.591046 chr12p13.2-p13.1 RAD51 associated protein 1
203236_s_at LGALS9 NM_009587 Hs.81337 chr17q11.1 Lectin, galactoside-binding, soluble, 9
(galectin 9)
207181_s_at CASP7 NM_001227 Hs.9216 chr10q25 Caspase 7, apoptosis-related cysteine
peptidase
219938_s_at PSTPIP2 NM_024430 Hs.567384 chr18q12 Proline-serine-threonine phosphatase
interacting protein 2
203217_s_at ST3GAL5 NM_003896 Hs.415117 chr2p11.2 ST3 beta-galactoside alpha-
2,3-sialyltransferase 5
219212_at HSPA14 NM_016299 Hs.534169 chr10p13 Heat shock 70kDa protein 14
204929_s_at VAMP5 NM_006634 Hs.172684 chr2p11.2 Vesicle-associated membrane protein 5
(myobrevin)
243_g_at MAP4 M64571 Hs.517949 chr3p21 Microtubule-associated protein 4
220966_x_at ARPC5L NM_030978 Hs.132499 chr9q33.3 Actin-related protein 2/3 complex,
subunit 5-like
202735_at EBP NM_006579 Hs.30619 chrXp11.23-p11.22 Emopamil binding protein (sterol
isomerase)
203805_s_at FANCA AW083279 Hs.567267 chr16q24.3 Fanconi anemia, complementation
group A
204279_at PSMB9 NM_002800 Hs.132682 chr6p21.3 Proteasome (prosome, macropain)
subunit, beta type, 9
204175_at ZNF593 NM_015871 –– chr1p36.11 Zinc finger protein 593
200814_at PSME1 NM_006263 Hs.75348 chr14q11.2 Proteasome (prosome, macropain)
activator subunit 1
204780_s_at FAS AA164751 Hs.244139 chr10q24.1 Fas (TNF receptor superfamily,
member 6)
219159_s_at SLAMF7 NM_021181 Hs.517265 chr1q23.1-q24.1 SLAM family member 7
219716_at APOL6 NM_030641 Hs.257352 chr22q12.3 Apolipoprotein L, 6
205569_at LAMP3 NM_014398 Hs.518448 chr3q26.3-q27 Lysosomal-associated membrane
protein 3
219148_at PBK NM_018492 Hs.104741 chr8p21.2 PDZ binding kinase
207509_s_at LAIR2 NM_002288 Hs.43803 chr19q13.4 Leukocyte-associated immunoglobulin-
like receptor 2
221345_at FFAR2 NM_005306 Hs.248056 chr19q13.1 Free fatty acid receptor 2
203755_at BUB1B NM_001211 Hs.631699 chr15q15 BUB1 budding uninhibited by
benzimidazoles 1 homolog
beta (yeast)
202702_at TRIM26 NM_003449 Hs.485041 chr6p21.3 Tripartite motif-containing 26
221816_s_at PHF11 BF055474 Hs.535080 chr13q14.3 PHD finger protein 11
202688_at TNFSF10 NM_003810 Hs.478275 chr3q26 Tumor necrosis factor (ligand)
superfamily, member 10
204639_at ADA NM_000022 Hs.255479 chr20q12-q13.11 Adenosine deaminase
204162_at KNTC2 NM_006101 Hs.414407 chr18p11.32 Kinetochore associated 2
204804_at TRIM21 NM_003141 Hs.632402 chr11p15.5 Tripartite motif-containing 21
203868_s_at VCAM1 NM_001078 Hs.109225 chr1p32-p31 Vascular cell adhesion molecule 1
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207375_s_at IL15RA NM_002189 Hs.524117 chr10p15-p14 Interleukin 15 receptor, alpha
219211_at USP18 NM_017414 Hs.38260 chr22q11.21 Ubiquitin specific peptidase 18
206247_at MICB NM_005931 Hs.211580 chr6p21.3 MHC class I polypeptide-related
sequence B
202870_s_at CDC20 NM_001255 Hs.524947 chr1p34.1 Cell division cycle 20 homolog
(S. cerevisiae)
208901_s_at TOP1 J03250 Hs.592136 chr20q12-q13.1 Topoisomerase (DNA) I
209666_s_at CHUK AF080157 Hs.198998 chr10q24-q25 Conserved helix-loop-helix ubiquitous
kinase
219607_s_at MS4A4A NM_024021 Hs.325960 chr11q12 Membrane-spanning 4-domains,
subfamily A, member 4
206919_at ELK4 NM_021795 Hs.497520 chr1q32 ELK4, ETS-domain protein
(SRF accessory protein 1)
215171_s_at TIMM17A AK023063 Hs.20716 chr1q32.1 Translocase of inner mitochondrial
membrane 17 homolog A (yeast)
202068_s_at LDLR NM_000527 Hs.213289 chr19p13.3 Low density lipoprotein receptor
(familial hypercholesterolemia)
204009_s_at KRAS W80678 Hs.505033 chr12p12.1 v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog
205687_at UBPH NM_019116 Hs.3459 chr16p12 Ubiquitin-binding protein homolog
202087_s_at CTSL NM_001912 Hs.418123 chr9q21-q22 Cathepsin L
216598_s_at CCL2 S69738 Hs.303649 chr17q11.2-q12 Chemokine (C-C motif) ligand 2
214933_at CACNA1A AA769818 Hs.501632 chr19p13.2-p13.1 Calcium channel, voltage-dependent,
P/Q type, alpha 1A subunit
203420_at FAM8A1 NM_016255 Hs.95260 chr6p22-p23 Family with sequence similarity 8,
member A1
203964_at NMI NM_004688 Hs.54483 chr2p24.3-q21.3 N-myc (and STAT) interactor
208969_at NDUFA9 AF050641 Hs.75227 chr12p13.3 NADH dehydrogenase (ubiquinone) 1
alpha subcomplex, 9, 39kDa
201664_at SMC4 AL136877 Hs.58992 chr3q26.1 Structural maintenance of
chromosomes 4
Poor outcome group: 208 downregulated genes
201892_s_at IMPDH2 NM_000884 Hs.476231 chr3p21.2 IMP (inosine monophosphate)
dehydrogenase 2
211937_at EIF4B NM_001417 Hs.292063 chr12q13.13 Eukaryotic translation initiation
factor 4B
200651_at GNB2L1 NM_006098 Hs.5662 chr5q35.3 Guanine nucleotide binding protein
(G protein)
203685_at BCL2 NM_000633 Hs.150749 chr18q21.33 B-cell CLL/lymphoma 2
221476_s_at RPL15 AF279903 Hs.381219 chr3p24.2 Ribosomal protein L15
218253_s_at LGTN NM_006893 Hs.497581 chr1q31-q32 Ligatin
200005_at EIF3S7 NM_003753 Hs.55682 chr22q13.1 Eukaryotic translation initiation
factor 3, subunit 7 zeta
219452_at DPEP2 NM_022355 Hs.372633 chr16q22.1 Dipeptidase 2
205019_s_at VIPR1 NM_004624 Hs.348500 chr3p22 Vasoactive intestinal peptide receptor 1
210908_s_at PFDN5 AB055804 –– chr12q12 Prefoldin subunit 5
214167_s_at RPLP0 AA555113 Hs.448226 chr12q24.2 Ribosomal protein, large, P0
205259_at NR3C2 NM_000901 Hs.163924 chr4q31.1 Nuclear receptor subfamily 3, group C,
member 2
210027_s_at APEX1 M80261 Hs.73722 chr14q11.2-q12 APEX nuclease (multifunctional DNA
repair enzyme) 1
200089_s_at RPL4 AI953886 Hs.644628 chr15q22 Ribosomal protein L4
201433_s_at PTDSS1 NM_014754 Hs.292579 chr8q22 Phosphatidylserine synthase 1
220755_s_at C6orf48 NM_016947 Hs.640836 chr6p21.3 Chromosome 6 open reading frame 48
200705_s_at EEF1B2 NM_001959 Hs.421608 chr2q33-q34 Eukaryotic translation elongation
factor 1 beta 2
200024_at RPS5 NM_001009 Hs.378103 chr19q13.4 Ribosomal protein S5
201064_s_at PABPC4 NM_003819 Hs.169900 chr1p32-p36 Poly(A) binding protein, cytoplasmic 4
(inducible form)
218997_at POLR1E NM_022490 Hs.591087 chr9p13.2 Polymerase (RNA) I polypeptide E,
53kDa
210715_s_at SPINT2 AF027205 Hs.31439 chr19q13.1 Serine peptidase inhibitor, Kunitz type, 2
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202283_at SERPINF1 NM_002615 Hs.645378 chr17p13.1 Serpin peptidase inhibitor, clade F
(alpha-2 antiplasmin
200937_s_at RPL5 NM_000969 Hs.532359 chr1p22.1 Ribosomal protein L5
216520_s_at TPT1 AF072098 Hs.374596 chr13q12-q14 Tumor protein, translationally
controlled 1
219549_s_at RTN3 NM_006054 Hs.473761 chr11q13 Reticulon 3
219922_s_at LTBP3 NM_021070 Hs.289019 chr11q12 Latent transforming growth factor beta
binding protein 3
219892_at TM6SF1 NM_023003 Hs.513094 chr15q24-q26 Transmembrane 6 superfamily
member 1
208631_s_at HADHA U04627 Hs.516032 chr2p23 Hydroxyacyl-coenzyme A
dehydrogenase
218495_at UXT NM_004182 Hs.172791 chrXp11.23-p11.22 Ubiquitously-expressed transcript
206559_x_at EEF1A1 NM_001403 –– chr6q14.1 Eukaryotic translation elongation
factor 1 alpha 1
200858_s_at RPS8 NM_001012 Hs.512675 chr1p34.1-p32 Ribosomal protein S8
217747_s_at RPS9 NM_001013 Hs.546288 chr19q13.4 Ribosomal protein S9
206760_s_at FCER2 NM_002002 Hs.465778 chr19p13.3 Fc fragment of IgE, low affinity II,
receptor for (CD23)
200032_s_at RPL9 NM_000661 Hs.513083 chr4p13 Ribosomal protein L9 /// ribosomal
protein L9
201258_at RPS16 NM_001020 Hs.397609 chr19q13.1 Ribosomal protein S16
205987_at CD1C NM_001765 Hs.132448 chr1q22-q23 CD1c molecule
206492_at FHIT NM_002012 Hs.196981 chr3p14.2 Fragile histidine triad gene
222212_s_at LASS2 AK001105 Hs.643565 chr1q21.2 LAG1 homolog, ceramide synthase 2
(S. cerevisiae)
204153_s_at MFNG NM_002405 Hs.517603 chr22q12 MFNG O-fucosylpeptide
3-beta-N-acetylglucosaminyltransferase
216032_s_at ERGIC3 AF091085 Hs.472558 chr20pter-q12 ERGIC and golgi 3
218084_x_at FXYD5 NM_014164 Hs.333418 chr19q12-q13.1 FXYD domain containing ion transport
regulator 5
207339_s_at LTB NM_002341 Hs.376208 chr6p21.3 Lymphotoxin beta (TNF superfamily,
member 3)
201276_at RAB5B AF267863 Hs.567328 chr12q13 RAB5B, member RAS oncogene family
206337_at CCR7 NM_001838 Hs.370036 chr17q12-q21.2 Chemokine (C-C motif) receptor 7 ///
chemokine (C-C motif) receptor 7
221558_s_at LEF1 AF288571 Hs.555947 chr4q23-q25 Lymphoid enhancer binding factor 1
214437_s_at SHMT2 NM_005412 Hs.75069 chr12q12-q14 Serine hydroxymethyltransferase 2
(mitochondrial)
203233_at IL4R NM_000418 Hs.513457 chr16p11.2-12.1 Interleukin 4 receptor
200909_s_at RPLP2 NM_001004 –– chr11p15.5-p15.4 Ribosomal protein, large, P2
203787_at SSBP2 NM_012446 Hs.102735 chr5q14.1 Single-stranded DNA binding protein 2
208754_s_at NAP1L1 AL162068 Hs.524599 chr12q21.2 Nucleosome assembly protein 1-like 1
210189_at HSPA1L D85730 Hs.558337 chr6p21.3 Heat shock 70kDa protein 1-like
200082_s_at RPS7 AI805587 Hs.534346 chr2p25 Ribosomal protein S
200034_s_at RPL6 NM_000970 Hs.528668 chr12q24.1 Ribosomal protein L6
201050_at PLD3 NM_012268 Hs.257008 chr19q13.2 Phospholipase D family, member 3
203385_at DGKA NM_001345 Hs.524488 chr12q13.3 Diacylglycerol kinase, alpha 80 kDa
200010_at RPL11 NM_000975 Hs.388664 chr1p36.1-p35 Ribosomal protein L11
203509_at SORL1 NM_003105 Hs.368592 chr11q23.2-q24.2 Sortilin-related receptor, L(DLR class)
A repeats-containing
200652_at SSR2 NM_003145 Hs.74564 chr1q21-q23 Signal sequence receptor
201136_at PLP2 NM_002668 Hs.77422 chrXp11.23 Proteolipid protein 2 (colonic
epithelium-enriched)
210949_s_at EIF3S8 BC000533 Hs.535464 chr16p11.2 Eukaryotic translation initiation
factor 3, subunit 8
212191_x_at RPL13 AW574664 Hs.410817 chr16q24.3 Ribosomal protein L13
209368_at EPHX2 AF233336 Hs.212088 chr8p21-p12 Epoxide hydrolase 2, cytoplasmic
208697_s_at EIF3S6 BC000734 Hs.405590 chr8q22-q23 Eukaryotic translation initiation
factor 3, subunit 6 48 kDa
208764_s_at ATP5G2 D13119 Hs.524464 chr12q13.13 ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit C2
(subunit 9)
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200823_x_at RPL29 NM_000992 Hs.425125 chr3p21.3-p21.2 Ribosomal protein L29
200936_at RPL8 NM_000973 Hs.178551 chr8q24.3 Ribosomal protein L8
201106_at GPX4 NM_002085 Hs.433951 chr19p13.3 Glutathione peroxidase 4 (phospholipid
hydroperoxidase)
203413_at NELL2 NM_006159 Hs.505326 chr12q13.11-q13.12 NEL-like 2 (chicken)
203818_s_at SF3A3 NM_006802 Hs.77897 chr1p34.3 Splicing factor 3a, subunit 3, 60 kDa
200081_s_at RPS6 BE741754 Hs.408073 chr9p21 Ribosomal protein S6 /// ribosomal
protein S6
217860_at NDUFA10 NM_004544 Hs.277677 chr2q37.3 NADH dehydrogenase (ubiquinone)
1 alpha subcomplex
208771_s_at LTA4H J02959 Hs.524648 chr12q22 Leukotriene A4 hydrolase
219528_s_at BCL11B NM_022898 Hs.510396 chr14q32.2 B-cell CLL/lymphoma 11B (zinc finger
protein)
221593_s_at RPL31 BC001663 Hs.469473 chr2q11.2 Ribosomal protein L31
201812_s_at TOMM7 NM_019059 Hs.380920 chr7p15.3 Translocase of outer mitochondrial
membrane 7 homolog (yeast)
200023_s_at EIF3S5 NM_003754 Hs.516023 chr11p15.4 Eukaryotic translation initiation
factor 3, subunit 5 epsilon
39318_at TCL1A X82240 Hs.2484 chr14q32.1 T-cell leukemia/lymphoma 1A
203547_at CD4 U47924 Hs.631659 chr12pter-p12 CD4 molecule /// CD4 molecule
207895_at NAALADL1 NM_005468 Hs.13967 chr11q12 N-acetylated alpha-linked acidic
dipeptidase-like 1
203113_s_at EEF1D NM_001960 Hs.333388 chr8q24.3 Eukaryotic translation elongation factor
1 delta 
200717_x_at RPL7 NM_000971 Hs.571841 chr8q21.11 Ribosomal protein L7
208703_s_at APLP2 BG427393 Hs.370247 chr11q23-q25 Amyloid beta (A4) precursor-like
protein 2
213093_at PRKCA AI471375 Hs.531704 chr17q22-q23.2 Protein kinase C, alpha
200695_at PPP2R1A NM_014225 Hs.467192 chr19q13.33 Protein phosphatase 2 (formerly 2A)
202179_at BLMH NM_000386 Hs.371914 chr17q11.2 Bleomycin hydrolase
200817_x_at RPS10 NM_001014 Hs.645317 chr6p21.31 Ribosomal protein S10
200965_s_at ABLIM1 NM_006720 Hs.438236 chr10q25 Actin binding LIM protein 1
201005_at CD9 NM_001769 Hs.114286 chr12p13.3 CD9 molecule
209504_s_at PLEKHB1 AF081583 Hs.445489 chr11q13.5-q14.1 Pleckstrin homology domain containing
200933_x_at RPS4X NM_001007 Hs.446628 chrXq13.1 Ribosomal protein S4, X-linked
204949_at ICAM3 NM_002162 Hs.75516 chr19p13.3-p13.2 Intercellular adhesion molecule 3
213762_x_at RBMX AI452524 Hs.380118 chrXq26.3 RNA binding motif protein, X-linked
203581_at RAB4A BC002438 Hs.296169 chr1q42-q43 RAB4A, member RAS oncogene family
217846_at QARS NM_005051 Hs.79322 chr3p21.3-p21.1 Glutaminyl-tRNA synthetase
202862_at FAH NM_000137 Hs.73875 chr15q23-q25 Fumarylacetoacetate hydrolase
(fumarylacetoacetase)
205039_s_at IKZF1 NM_006060 Hs.488251 chr7p13-p11.1 IKAROS family zinc finger 1 (Ikaros)
200008_s_at GDI2 D13988 Hs.299055 chr10p15 GDP dissociation inhibitor 2 /// GDP
dissociation inhibitor 2
210786_s_at FLI1 M93255 Hs.504281 chr11q24.1-q24.3 Friend leukemia virus integration 1
204777_s_at MAL NM_002371 Hs.80395 chr2cen-q13 Mal, T-cell differentiation protein
209264_s_at TSPAN4 AF054841 Hs.437594 chr11p15.5 Tetraspanin 4
200736_s_at GPX1 NM_000581 Hs.76686 chr3p21.3 Glutathione peroxidase 1
201417_at SOX4 AL136179 Hs.643910 chr6p22.3 SRY (sex determining region Y)-box 4
203088_at FBLN5 NM_006329 Hs.332708 chr14q32.1 Fibulin 5
200036_s_at RPL10A NM_007104 Hs.546269 chr6p21.3-p21.2 Ribosomal protein L10a
200053_at SPAG7 NM_004890 Hs.90436 chr17p13.2 Sperm associated antigen 7
200018_at RPS13 NM_001017 Hs.446588 chr11p15 Ribosomal protein S13
212271_at MAPK1 AA195999 Hs.431850 chr22q11.2 Mitogen-activated protein kinase 1
200763_s_at RPLP1 NM_001003 Hs.356502 chr15q22 Ribosomal protein, large, P1
208822_s_at DAP3 U18321 Hs.516746 chr1q21-q22 Death associated protein 3
214470_at KLRB1 NM_002258 Hs.169824 chr12p13 Killer cell lectin-like receptor subfamily B,
member 1
217969_at C11orf2 NM_013265 Hs.277517 chr11q13 Chromosome 11 open reading frame2
220753_s_at CRYL1 NM_015974 Hs.370703 chr13q12.11 Crystallin, lambda 1
200602_at APP NM_000484 Hs.651215 chr21q21.2-21q21.3 Amyloid beta (A4) precursor protein
(peptidase nexin-II, Alzheimer disease)
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206343_s_at NRG1 NM_013959 Hs.453951 chr8p21-p12 Neuregulin 1
203723_at ITPKB NM_002221 Hs.528087 chr1q42.13 Inositol 1,4,5-trisphosphate 3-kinase B
219700_at PLXDC1 NM_020405 Hs.125036 chr17q21.1 Plexin domain containing 1
200099_s_at RPS3A AL356115 Hs.356572 chr4q31.2-q31.3 Ribosomal protein S3A
200013_at RPL24 NM_000986 Hs.477028 chr3q12 Ribosomal protein L24 /// ribosomal
protein L24
201256_at COX7A2L NM_004718 Hs.339639 chr2p21 Cytochrome c oxidase subunit VIIa
polypeptide 2 like
200716_x_at RPL13A NM_012423 Hs.523185 chr19q13.3 Ribosomal protein L13a
208591_s_at PDE3B NM_000922 Hs.445711 chr11p15.1 Phosphodiesterase 3B, cGMP-inhibited
204612_at PKIA NM_006823 Hs.433700 chr8q21.12 Protein kinase (cAMP-dependent,
catalytic) inhibitor alpha
217989_at HSD17B11 NM_016245 Hs.282984 chr4q22.1 Hydroxysteroid (17-beta) 
dehydrogenase 11
204628_s_at ITGB3 NM_000212 Hs.218040 chr17q21.32 Integrin, beta 3 (platelet glycoprotein
IIIa, antigen CD61)
201968_s_at PGM1 NM_002633 Hs.1869 chr1p31 Phosphoglucomutase 1
212063_at CD44 BE903880 Hs.502328 chr11p13 CD44 molecule (Indian blood group)
218918_at MAN1C1 NM_020379 Hs.197043 chr1p35 Mannosidase, alpha, class 1C,
member 1
200093_s_at HINT1 N32864 Hs.483305 chr5q31.2 Histidine triad nucleotide binding
protein 1
206220_s_at RASA3 NM_007368 Hs.369188 chr13q34 RAS p21 protein activator 3
221564_at PRMT2 AL570294 Hs.154163 chr21q22.3 Protein arginine methyltransferase 2
220948_s_at ATP1A1 NM_000701 Hs.371889 chr1p21 ATPase, Na+/K+ transporting,
alpha 1 polypeptide
211954_s_at RANBP5 BC000947 Hs.643743 chr13q32.2 RAN binding protein 5
201350_at FLOT2 NM_004475 Hs.514038 chr17q11-q12 Flotillin 2
202554_s_at GSTM3 AL527430 Hs.2006 chr1p13.3 Glutathione S-transferase M3 (brain)
221494_x_at EIF3S12 AF085358 Hs.314359 chr19q13.2 Eukaryotic translation initiation
factor 3, subunit 12
200962_at RPL31 AI348010 Hs.647888 chr2q11.2 Ribosomal protein L31
201030_x_at LDHB NM_002300 Hs.446149 chr12p12.2-p12.1 Lactate dehydrogenase B
200644_at MARCKSL1 NM_023009 Hs.75061 chr1p35.1 MARCKS-like 1
204490_s_at CD44 M24915 Hs.502328 chr11p13 CD44 molecule (Indian blood group)
204718_at EPHB6 NM_004445 Hs.380089 chr7q33-q35 EPH receptor B6
210978_s_at TAGLN2 BC002616 Hs.517168 chr1q21-q25 Transgelin 2
208852_s_at CANX AI761759 Hs.651169 chr5q35 Calnexin
220606_s_at C17orf48 NM_020233 Hs.47668 chr17p13.1 Chromosome 17 open reading frame 48
206674_at FLT3 NM_004119 Hs.507590 chr13q12 Fms-related tyrosine kinase 3
204102_s_at EEF2 NM_001961 Hs.515070 chr19pter-q12 Eukaryotic translation elongation
factor 2
202247_s_at MTA1 BE561596 Hs.525629 chr14q32.3 Metastasis associated 1
208692_at RPS3 U14990 Hs.334176 chr11q13.3-q13.5 Ribosomal protein S3
200094_s_at EEF2 AI004246 Hs.515070 chr19pter-q12 Eukaryotic translation elongation
factor 2
217990_at GMPR2 NM_016576 Hs.368855 chr14q12 Guanosine monophosphate reductase 2
200012_x_at RPL21 NM_000982 Hs.632169 chr13q12.2 Ribosomal protein L21
200057_s_at NONO NM_007363 Hs.533282 chrXq13.1 Non-POU domain containing,
octamer-binding
208796_s_at CCNG1 BC000196 Hs.79101 chr5q32-q34 Cyclin G1
215739_s_at TUBGCP3 AJ003062 Hs.224152 chr13q34 Tubulin, gamma complex associated
protein 3
208478_s_at BAX NM_004324 Hs.631546 chr19q13.3-q13.4 BCL2-associated X protein
200674_s_at RPL32 NM_000994 Hs.265174 chr3p25-p24 Ribosomal protein L32
208645_s_at RPS14 AF116710 Hs.381126 chr5q31-q33 Ribosomal protein S14
212032_s_at PTOV1 AL046054 –– chr19q13.33 Prostate tumor overexpressed gene 1
218338_at PHC1 NM_004426 Hs.305985 chr12p13 Polyhomeotic homolog 1 (Drosophila)
201432_at CAT NM_001752 Hs.502302 chr11p13 Catalase
202731_at PDCD4 NM_014456 Hs.232543 chr10q24 Programmed cell death 4 (neoplastic
transformation inhibitor)
201118_at PGD NM_002631 Hs.464071 chr1p36.3-p36.13 Phosphogluconate dehydrogenase
212642_s_at HIVEP2 AL023584 Hs.510172 chr6q23-q24 Human immunodeficiency virus type I
enhancer binding protein 2
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202736_s_at LSM4 AA112507 Hs.515255 chr19p13.11 LSM4 homolog, U6 small nuclear RNA
associated (S. cerevisiae)
208768_x_at RPL22 D17652 Hs.515329 chr1p36.3-p36.2 Ribosomal protein L22
201049_s_at RPS18 NM_022551 Hs.627414 chr6p21.3 Ribosomal protein S18
200074_s_at RPL14 U16738 Hs.446522 chr3p22-p21.2 Ribosomal protein L14
65588_at LOC388796 AA827892 Hs.400876 chr20q11.23 Hypothetical LOC388796
206686_at PDK1 NM_002610 Hs.470633 chr2q31.1 Pyruvate dehydrogenase kinase,
isozyme 1
200022_at RPL18 NM_000979 Hs.515517 chr19q13 Ribosomal protein L18 /// ribosomal
protein L18
201622_at SND1 NM_014390 Hs.122523 chr7q31.3 Staphylococcal nuclease and tudor
domain containing 1
217870_s_at CMPK NM_016308 Hs.11463 chr1p32 Cytidylate kinase
220773_s_at GPHN NM_020806 Hs.208765 chr14q23.3 Gephyrin
200804_at TEGT NM_003217 Hs.35052 chr12q12-q13 Testis enhanced gene transcript
(BAX inhibitor 1)
202105_at IGBP1 NM_001551 Hs.496267 chrXq13.1-q13.3 Immunoglobulin (CD79A) binding
protein 1
200061_s_at RPS24 BC000523 Hs.356794 chr10q22-q23 Ribosomal protein S24 /// ribosomal
protein S24
200095_x_at RPS10 AA320764 Hs.645317 chr6p21.31 ribosomal protein S10 /// ribosomal 
rotein S10
204892_x_at EEF1A1 NM_001402 Hs.586423 chr6q14.1 Eukaryotic translation elongation
factor 1 alpha 1
202213_s_at CUL4B AI650819 Hs.102914 chrXq23 Cullin 4B
200002_at RPL35 NM_007209 Hs.182825 chr9q34.1 Ribosomal protein L35 /// ribosomal
protein L35
200990_at TRIM28 NM_005762 Hs.467408 chr19q13.4 Tripartite motif-containing 28
203865_s_at ADARB1 NM_015833 Hs.474018 chr21q22.3 Adenosine deaminase, RNA-specific,
B1 (RED1 homolog rat)
220001_at PADI4 NM_012387 Hs.522969 chr1p36.13 Peptidyl arginine deiminase, type IV
215813_s_at PTGS1 S36219 Hs.201978 chr9q32-q33.3 Prostaglandin-endoperoxide synthase 1
208700_s_at TKT L12711 Hs.89643 chr3p14.3 Transketolase (Wernicke-Korsakoff
syndrome)
202990_at PYGL NM_002863 Hs.282417 chr14q21-q22 Phosphorylase, glycogen
212716_s_at EIF3S12 AW083133 Hs.314359 chr19q13.2 Eukaryotic translation initiation
factor 3, subunit 12
209185_s_at IRS2 AF073310 Hs.442344 chr13q34 Insulin receptor substrate 2
221989_at RPL10 AW057781 Hs.534404 chrXq28 Ribosomal protein L10
214359_s_at HSP90AB1 AI218219 Hs.509736 chr6p12 Heat shock protein 90kDa alpha
(cytosolic), class B member 1
201393_s_at IGF2R NM_000876 Hs.487062 chr6q26 Insulin-like growth factor 2 receptor
201257_x_at RPS3A NM_001006 Hs.356572 chr4q31.2-q31.3 Ribosomal protein S3A
205408_at MLLT10 NM_004641 Hs.30385 chr10p12 Myeloid/lymphoid or mixed-lineage
leukemia (trithorax homolog,
Drosophila)
218679_s_at VPS28 NM_016208 Hs.418175 chr8q24.3 Vacuolar protein sorting 28 homolog
(S. cerevisiae)
202096_s_at TSPO NM_000714 Hs.202 chr22q13.31 Translocator protein (18 kDa)
211558_s_at DHPS U26266 Hs.79064 chr19p13.2-p13.1 Deoxyhypusine synthase
205055_at ITGAE NM_002208 Hs.513867 chr17p13 Integrin, alpha E (antigen CD103,
human mucosal lymphocyte
antigen 1
204867_at GCHFR NM_005258 Hs.631717 chr15q15 GTP cyclohydrolase I feedback regulator
200971_s_at SERP1 NM_014445 Hs.518326 chr3q25.1 Stress-associated endoplasmic
reticulum protein 1
203579_s_at SLC7A6 AI660619 Hs.334848 chr16q22.1 Solute carrier family 7 (cationic amino
acid transporter, y+ system),
member 6
39249_at AQP3 AB001325 Hs.234642 chr9p13 Aquaporin 3 (Gill blood group)
203408_s_at SATB1 NM_002971 Hs.517717 chr3p23 Special AT-rich sequence binding protein 1




205026_at STAT5B NM_012448 Hs.632256 chr17q11.2 Signal transducer and activator of
transcription 5B
212257_s_at SMARCA2 AW131754 Hs.298990 chr9p22.3 SWI/SNF related, matrix associated
220500_s_at RABL2B NM_007082 Hs.446425 chr22q13.33 RAB, member of RAS oncogene
family-like 2B
212400_at FAM102A AL043266 Hs.568044 chr9q34.11 Family with sequence similarity 102,
member A
202974_at MPP1 NM_002436 Hs.496984 chrXq28 Membrane protein, palmitoylated 1,
55 kDa
213566_at RNASE6 NM_005615 Hs.23262 chr14q11.2 Ribonuclease, RNase A family
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